GSK Forecast: New CEO Luke Miels Warns of Slower Sales Growth Ahead

GSK has released its first sales outlook under new CEO Luke Miels, indicating a slowdown in growth for 2026 compared with the previous year. The British pharmaceutical company is balancing a research pipeline expansion with looming patent expiries for its top-selling HIV treatments. While the company expects moderate revenue growth, investor attention remains on new product launches, strategic acquisitions, and operational execution under the new leadership.